Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.

[D.ap]

Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
Thu Aug 23, 2018 7:23 am

Abstract
OBJECTIVES: Patients treated with nivolumab often experience its unique adverse events, called immune-related adverse events (irAEs). Regarding the mechanisms of immune-checkpoint inhibitors (ICIs), the occurrence of irAEs may also reflect antitumor responses. Here, we report the clinical correlation between irAEs and efficacy in NSCLC patients treated with nivolumab.

https://www.ncbi.nlm.nih.gov/m/pubmed/29290265/